The Journal of Thrombosis and Haemostasis (JTH) has accepted the following articles on recommendations from the Pediatric/Neonatal Hemostasis and Thrombosis SSC Subcommittee: Development of New Anticoagulant Drugs for Pediatric Use There has been a notable increase in venous thromboembolism (VTE) and anticoagulant use in children. As a result of new regulations in the United States and Europe requiring pharmaceutical companies to develop and license new drugs for children, pediatric investigation programs (PIP) for several new anticoagulants have begun. The Pediatric/Neonatal Hemostasis and Thrombosis SSC Subcommittee is proposing a guidance paper to ensure a rational and harmonized approach to the introduction of new anticoagulants into pediatrics.
View the Accepted Article of recommendations on this topic from the JTH here. Assessment of Non-extremity Venous Thromboembolism Outcomes Post-thrombotic syndrome (PTS) is an important outcome after venous thromboembolism (VTE) and recommendations for standardized measurements following extremity VTE have been published. However, the clinical spectrum of pediatric VTE extends beyond extremities in approximately 25-30% of children, and long-term outcomes after non-extremity VTE have not been measured. As such outcomes are site-dependent and the clinical spectrum is heterogeneous, currently available PTS outcome scales are inadequate for the measurement.